GlassScriptPhysician profile
Stephen V Streitfeld
NPI 1306883293
$6,235.77
in general payments reported to CMS, 2019-2025
27 companies · $1,172 in 2025
The $1,172 reported for 2025 was more than what 83% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $685 · 2021: $911 · 2022: $847 · 2023: $924 · 2024: $1,061 · 2025: $1,172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,489.60 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $669.50 | 2019-2025 | Trintellix |
| Sunovion Pharmaceuticals INC. | $624.60 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $411.27 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $406.09 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $395.31 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Lundbeck LLC | $362.63 | 2021-2025 | Rexulti |
| Allergan, INC. | $317.99 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $190.30 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $175.00 | 2019 | |
| Bausch Health US, LLC | $172.47 | 2019-2024 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $148.33 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $133.70 | 2023-2025 | Auvelity |
| Jazz Pharmaceuticals INC. | $101.29 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.78 | 2021-2023 | Abilify Maintena |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $87.83 | 2022-2025 | Azstarys |
| Almatica Pharma LLC | $76.91 | 2021-2025 | Loreev Xr |
| Merck Sharp & Dohme LLC | $66.17 | 2020-2021 | |
| Supernus Pharmaceuticals, INC. | $58.14 | 2021-2025 | Qelbree |
| Shire North American Group INC | $58.04 | 2019 | |
| Idorsia Pharmaceuticals US INC | $52.97 | 2023-2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $43.03 | 2025 | Cobenfy |
| Eisai INC. | $32.64 | 2020 | |
| Vanda Pharmaceuticals INC. | $27.20 | 2024 | Fanapt |
| Ironshore Pharmaceuticals INC. | $15.83 | 2019 | |
| Adlon Therapeutics L.P. | $14.66 | 2020 | |
| Arbor Pharmaceuticals, INC. | $13.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Streitfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.